Pioneering startup in AI-driven prognosis tests for cancer treatment Spotlight Medical announced on Friday a EUR6.2m seed funding round led by Kurma Partners and Heal Capital.
This funding will bring its first prognosis test to the clinic, marking a significant milestone in commercializing AI-based cancer solutions. Spotlight Medical leverages decades of patient treatment data to prevent over or undertreatment, enhancing cancer outcomes.
Founded in 2024, Spotlight Medical is supported by esteemed cancer centres Institut Curie and Gustave Roussy. The company is dedicated to developing clinical tests that utilize vast patient data.
Advanced AI algorithms will provide a concrete AI-based solution for cancer patients, significantly improving treatment precision.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen